180
Views
6
CrossRef citations to date
0
Altmetric
Original Research

Sputum Protein Biomarkers in Airway Diseases: A Pilot Study

, , , , , , , , & show all
Pages 2203-2215 | Published online: 28 Jul 2021

References

  • American Thoracic Society. What constitutes an adverse health effect of air pollution? Official statement of the American Thoracic Society. Am J Respir Crit Care Med. 2000;161:665–673.
  • Jinnai M, Niimi A, Ueda T, et al. Induced sputum concentrations of mucin in patients with asthma and chronic cough. Chest. 2010;137(5):1122–1129.
  • Vestbo J, Prescott E, Lange P. Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Am J RespirCrit Care Med. 1996;153:1530–1535.
  • Sherman CB, Xu X, Speizer FE, Ferris BG Jr, Weiss ST, Dockery DW. Longitudinal lung function decline in subjects with respiratorysymptoms. Am Rev Respir Dis. 1992;146:855–859.
  • Kim V, Han MK; COPDGene Investigators, et al. The chronic bronchitic phenotype of COPD: an analysis of the COPDGene Study. Chest. 2011;140(3):626–633.
  • Agusti A, Calverley PM, Celli B, et al. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res. 2010;11:122.
  • de Oca MM, Halbert RJ, Lopez MV, et al. The chronic bronchitis phenotype in subjects with and withoutCOPD: the PLATINO study. EurRespir J. 2012;40:28–36.
  • Burgel PR, Nesme-Meyer P, Chanez P, et al. Cough and sputum production are associated with frequent exacerbations and hospitalizations in COPD subjects. Chest. 2009;135:975–982.
  • Prescott E, Lange P, Vestbo J. Chronic mucus hypersecretion in COPD and death from pulmonary infection. EurRespir J. 1995;8:1333–1338.
  • Allinson JP, Hardy R, Donaldson GC, Shaheen SO, Kuh D, Wedzicha JA. The presence of chronic mucus hypersecretion across adult life in relation to chronic obstructive pulmonary disease development. Am J Respir Crit Care Med. 2016;193(6):662–672. doi:10.1164/rccm.201511-2210OC
  • Ferris BG. Epidemiology standardization project (American Thoracic Society). Am Rev Respir Dis. 1978;118(6 Pt 2):1–120.
  • Pizzichini E, Pizzichini MM, Efthimiadis A, et al. Indices of airway inflammation in induced sputum: reproducibility and validity of cell and fluid-phase measurements. Am J Respir Crit Care Med. 1996;154(2 Pt 1):308–317.
  • Fahy JV, Dickey BF. Airway mucus function and dysfunction. N Engl J Med. 2010;363(23):2233–2247.
  • Nicholas B, Skipp P, Mould R, et al. Shotgun proteomic analysis of human-induced sputum. Proteomics. 2006;6(15):4390–4401.
  • Gray RD, MacGregor G, Noble D, et al. Sputum proteomics in inflammatory and suppurative respiratory diseases. Am J Respir Crit Care Med. 2008;178(5):444–452.
  • Gharib SA, Nguyen EV, Lai Y, Plampin JD, Goodlett DR, Hallstrand TS. Induced sputum proteome in healthy subjects and asthmatic patients. J Allergy Clin Immunol. 2011;128(6):1176–1184.e6.
  • Ohlmeier S, Mazur W, Linja-Aho A, et al. Sputum proteomics identifies elevated PIGR levels in smokers and mild-to-moderate COPD. J Proteome Res. 2012;11(2):599–608.
  • Takahashi K, Pavlidis S, Ng Kee Kwong F; on behalf of the U-BIOPRED study group, et al. Sputum proteomics and airway cell transcripts of current and ex-smokers with severe asthma in U-BIOPRED: an exploratory analysis. Eur Respir J. 2018;51(5):1702173.
  • Reidel B, Radicioni G, Clapp PW, et al. E-Cigarette use causes a unique innate immune response in the lung, involving increased neutrophilic activation and altered mucin secretion. Am J Respir Crit Care Med. 2018;197(4):492–501.
  • Schofield JPR, Burg D, Nicholas B; U-BIOPRED Study Group, et al. Stratification of asthma phenotypes by airway proteomic signatures. J Allergy Clin Immunol. 2019;144(1):70–82.
  • Welsh KG, Rousseau K, Fisher G, et al. MUC5AC and a glycosylated variant of MUC5B alter mucin composition in children with acute asthma. Chest. 2017;152(4):771–779.
  • Kesimer M, Ford AA, Ceppe A, et al. Airway mucin concentration as a marker of chronic bronchitis. N Engl J Med. 2017;377(10):911–922.
  • Singh D, Agusti A, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease: the GOLD science committee report 2019. Eur Respir J. 2019;53;5:1900164.
  • Boulet LP, Reddel HK, Bateman E, Pedersen S, FitzGerald JM, O’Byrne PM. The Global Initiative for Asthma (GINA): 25 years later. Eur Respir J. 2019;54(2):1900598.
  • Lefaudeux D, De Meulder B; U-BIOPRED Study Group, et al. U-BIOPRED clinical adult asthma clusters linked to a subset of sputum omics. J Allergy Clin Immunol. 2017;139(6):1797–1807.
  • Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest. 2000;117(5 Suppl 2):398S–401S.
  • Ray Y, Paul SR, Bandopadhyay P, et al. Clinical and immunological benefits of convalescent plasma therapy in severe COVID-19: insights from a single center open label randomised control trial. medRxiv. 2020. doi:10.1101/2020.11.25.20237883